Stock VNDA VANDA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Real-time Estimate Cboe BZX
Other stock markets
 09:58:22 2024-04-29 EDT 		5-day change 1st Jan Change
4.775 USD +3.35% Intraday chart for Vanda Pharmaceuticals Inc. -2.19% +11.26%
04-25 Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer RE
04-22 Vanda Pharmaceuticals Appeal for Patents on Sleep Drug Declined by US Supreme Court MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shareholder Capital asks Vanda Pharma's board to reconsider Future Pak's offer
U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
Butler Hall Capital urges Vanda to engage in sales discussions
Deals of the day-Mergers and acquisitions
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., State Street Corporation, BlackRock, Inc., Dimensional Fund Advisors LP and others.
Top Midday Gainers
Vanda Pharmaceuticals Shares Soar After FDA Approval for Bipolar I Disorder Therapy
Wall Street nach neuen US-Daten schwächer
Powell Speech Eyed, Intel Weighs on Sentiment as US Equity Futures Waver Premarket
Sector Update: Health Care
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Bets Lean Towards Smaller Rate Cuts
Top Premarket Gainers
Vanda Pharmaceuticals Secures FDA Approval for Bipolar I Disorder Therapy; Shares Rise Pre-Bell
US FDA approves Vanda's drug for treatment of bipolar disorder
US FDA approves Vanda's drug for bipolar disorder
Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. News Vanda Pharmaceuticals Inc.
  5. Other languages